• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

Drug for children with spinal muscular atrophy too expensive, HSE says

firstwordpharmaFebruary 23, 2019

Tag: HSE , Spinal Muscular Atrophy , Children

  • The Health Service Executive has determined that the spinal muscle atrophy drug Spinraza is not cost-effective at its current price, The Irish Times reported Friday.

  • The HSE determined that the treatment could carry a cost of 20 million euros over five years, while it was not able to reach an accord with the manufacturer regarding a viable price.

  • The regulator noted that Spinraza would carry a cost of  600 000 euros for the first year and 380 000 euros for each successive year.

  • The HSE stated that it was "obligated to ensure that expenditure of this scale must represent evidence of clinical and cost-effectiveness."

  • Register as Visitor to CPhI China 2019!

Previous:Delhi HC sets aside govt ban on Lupin's anti-diabetic drug Gluconorm-30

Next:Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Drug for children with spinal muscular atrophy too expensive, HSE says | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

FMOC-L-HSE(TRT)-OH

FMOC-L-HSE(TRT)-OH
printed children resistant foil

printed children resistant foil

Identification Band (Adult, Children)

Identification Band (Adult, Children)
Children

Children
PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM
LINCOMYCIN HCL

LINCOMYCIN HCL
GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides
CEFALEXINE cephalosporins

CEFALEXINE cephalosporins
CEFRADINE cephalosporins

CEFRADINE cephalosporins
CEFADROXIL cephalosporins

CEFADROXIL cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service